Astellas gives updates on Izervay security, part 1 geographic atrophy trial

Date:


July 07, 2024

2 min watch


We had been unable to course of your request. Please attempt once more later. In case you proceed to have this difficulty please contact [email protected].

PARK CITY, Utah — On this Healio Video Perspective from Medical Trials on the Summit, Carolyn Sasse of Astellas highlights the corporate’s ophthalmology pipeline.

Sasse gives updates about post-marketing security information for Izervay (avacincaptad pegol intravitreal resolution) and a part 1 trial that’s at the moment recruiting sufferers with geographic atrophy secondary to age-related macular degeneration.

“Over the previous decade, now we have established a number one early-stage ophthalmology pipeline that features cell and gene therapies to deal with illnesses corresponding to geographic atrophy and glaucoma, in addition to inherited retinal illnesses corresponding to Stargardt and retinitis pigmentosa,” she mentioned.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

Popular

More like this
Related

The Vitamin Shoppe’s Father or mother Firm Information for Chapter, Enterprise Stays Sturdy

On Nov. 3, Franchise Group Inc. (FRG, Delaware,...

Be a part of the AK Cookbook Membership

Welcome to December’s AK Cookbook Membership! I’m so...

Does Pre-Exercise Break a Quick?

In case you’re following an intermittent fasting food...

Steak Suggestions – Seasonal Cravings

Revealed: Dec 4, 2024 Modified: Dec 4, 2024...